Immunotoxins, formulations thereof and their use in medicine
AssigneeXenikos B.V.
InventorsHenricus Gerardus Van Hooren, Maarten Jaap Frijlink, Ypke Vincentius Johannes Maria Van Oosterhout
Life of this patent
Estimating the term…
Abstract
The present invention provides a composition comprising a first antibody molecule that specifically recognizes CD3 and a second antibody molecule that specifically recognizes CD7, for use in a method of treatment, or preventative treatment of viral infection or viral reactivation in a mammalian subject undergoing immunomodulatory treatment, wherein the first and second antibody molecules are each provided with a toxic moiety. Also provided is a method of treating a mammalian subject having, or being at risk of developing, chronic Graft versus Host disease (cGVHD). Also provided is a related pharmaceutical composition.
Claims25
A pharmaceutical composition comprising:
- (i) a first monoclonal antibody that recognizes CD3 having a heavy chain variable region comprising a complementarity determining region 1 (CDRH1) comprising the amino acid sequence of SEQ ID NO:
- 5;
- a complementarity determining region 2 (CDRH2) comprising the amino acid sequence of SEQ ID NO:
- 6;
- and a complementarity determining region 3 (CDRH3) comprising the amino acid sequence of SEQ ID NO:
- 7;
- and
- a light chain variable region comprising a complementarity determining region 1 (CDRL1) comprising the amino acid sequence of SEQ ID NO:
- 8;
- a complementarity determining region 2 (CDRL2) comprising the amino acid sequence of SEQ ID NO:
- 9, and a complementarity determining region 3 (CDRL3) comprising the amino acid sequence of SEQ ID NO:
- 10, wherein the first antibody is conjugated to at least one ricin toxin A (RTA), and
- a second monoclonal antibody that recognizes CD7 having a heavy chain variable region comprising a CDRH1 comprising the amino acid sequence of SEQ ID NO:
- 15;
- a CDRH2 comprising the amino acid sequence of SEQ ID NO:
- 16;
- and a CDRH3 comprising the amino acid sequence of SEQ ID NO:
- 17;
- and
- a light chain variable region comprising a CDRL1 comprising the amino acid sequence of SEQ ID NO:
- 18;
- a CDRL2 comprising the amino acid sequence of SEQ ID NO:
- 19, and a CDRL3 comprising the amino acid sequence of SEQ ID NO:
- 20, wherein the second antibody is conjugated to at least one ricin toxin A (RTA);
- (ii) 5 to 20 mM of a citrate buffer;
- (iii) 50 to 300 mM of L-arginine or a pharmaceutically acceptable salt thereof;
- (iv) 0.01 to 0.1% (w/v) of a polysorbate;
- and
- (v) 120 to 160 mM maltose,
- wherein the composition is in water and has a pH in the range 6 to 7.5.
Dependencies are inferred from the claim text.